NetraMark’s AI to Revolutionize Clinical Trials
Company Announcements

NetraMark’s AI to Revolutionize Clinical Trials

Netramark Holdings Inc (TSE:AIAI) has released an update.

NetraMark Holdings Inc. has entered into a contract with an undisclosed pharmaceutical company to leverage its NetraAI technology for enhancing clinical trial efficacy and reducing placebo responses. The AI-driven analytics are set to streamline the trial process by identifying key criteria, which could lead to more significant results with fewer patients, potentially accelerating the time and reducing costs for product approval. This collaboration underscores NetraMark’s role in advancing clinical research by offering actionable insights and optimizing trial designs.

For further insights into TSE:AIAI stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskNetraMark Appoints Oncology Expert P.J. Haley to Board
TipRanks Canadian Auto-Generated NewsdeskNetraMark Unveils New Suite to Revolutionize Clinical Trials
TipRanks Canadian Auto-Generated NewsdeskNetraMark’s Q3 Success with AI Clinical Trial Analytics
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App